메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Th…

SHANGHAI and HONG KONG, Aug. 19, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that its in-house discovered CLDN18.2 ADC, ATG-022,was granted a Breakthrough Therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of CLDN18.2-positive, HER-2 negative unre
- 김갑성 기자
- 2025-08-19 13:26
Tigermed Receives MSCI ESG AAA Rating

HANGZHOU, China, Aug. 19, 2025 -- Tigermed is proud to announce that it has been awarded an MSCI Environmental, Social, and Governance (ESG) Rating of AAA, the highest rating in the industry. This recognition underscores our commitment to excellence in ESG practices, positioning us as a leader in sustainable business performance. MSCI's AAA rating is reserved for companies that demonstrate superior ESG performance and strong resilience to long-term risks. It reflects Tigermed's consistent efforts to integrate ESG principles into our core operations and strategic decision-making.
- 김갑성 기자
- 2025-08-19 11:15
Beyfortus® (nirsevimab) approved in Singapore to protect all…

[ 메디채널 김갑성 기자 ] Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the real world.[1] In the recent HARMONIE trial findings, Beyfortus reduced RSV hospitalisations in infants by 82.7% (95% CI: 67.8 to 91.5; p<0,0001) through six months (180 days). [2], [3] Administration can be timed during the first year of life to provide protection from birth, or as early as possible. SINGAPORE, Aug. 19, 2025 -- The Health Sciences Authority (HSA)
- 김갑성 기자
- 2025-08-19 11:00
RemeGen and Santen Enter into Exclusive Licensing Agreem…

YANTAI, China, Aug. 19, 2025 -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd. ("Santen"). Under the agreement, Santen China has obtained exclusive rights to develop, manufacture, and commercialize RC28-E in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan) as well as in South Korea, Thailand, Vietna
- 김갑성 기자
- 2025-08-19 08:00
openRxiv names Dr. Tracy Teal first CEO to advance open sc…

[ 메디채널 김갑성 기자 ] Scientist and nonprofit leader who previously led The Carpentries and Dryad to lead the organization that oversees bioRxiv and medRxiv. DAVIS, Calif., Aug. 19, 2025 -- openRxiv announced today that after an extensive international search, its Board of Directors has appointed Dr. Tracy Teal as the organization's inaugural CEO. Dr. Teal has served as interim COO of openRxiv since its launch as an independent non-profit in March of this year, playing a central role in launching the organization and establishing its stewardship of bioRxiv and medRxiv, two of the world's m
- 김갑성 기자
- 2025-08-19 00:00
Ansell Receives Frost & Sullivan's 2025 Global Sustainable Hos…

[ 메디채널 김갑성 기자 ] Ansell is recognised for its leadership in hospital supply sustainability, visionary innovation, and customer impact on a global scale. SAN ANTONIO, Aug. 18, 2025 -- Frost & Sullivan, a leader in the information and growth advisory industry, has awarded the title of "2025 Global Sustainable Hospital Supplies Company of the Year" to Ansell, a global provider of safety solutions. Recognised for its outstanding achievements in innovation and customer impact, Ansell is focused on driving sustainable innovation by using fewer or safer materials and continuous
- 김갑성 기자
- 2025-08-18 22:00
Aon Announces Strategic Investment in eMed to Scale GLP-1…

[ 메디채널 김갑성 기자 ] Strategic investment is accelerating the transformation of employer-focused obesity solutions to boost adherence, retention and deliver breakthrough health outcomes with cost savings DUBLIN, Aug. 18, 2025 -- Aon plc (NYSE: AON), a leading global professional services firm, today announced a strategic investment in eMed Population Health, Inc., an emerging leader in the delivery of GLP-1 programs. The partnership will enhance employer sponsored access to GLP-1 therapies and scale solutions for obesity. The investment follows the launch earlier this year of Aon's
- 김갑성 기자
- 2025-08-18 21:30
Datasea Achieves Breakthrough in Acoustic Technology, A…

DTSS' Acoustic innovation Addresses the Healthcare Application Market Projected to Exceed $100 Billion in China and Approach $90 Billion Globally by 2030 BEIJING, Aug. 18, 2025 -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a Nevada-based technology enterprise specializing in advanced acoustic high-tech products and AI multimodal digital solutions, today announced a milestone breakthrough in its acoustic technology. The Company has successfully achieved an exciting leap forward in its acoustic core technologies with the integration of sound wa
- 김갑성 기자
- 2025-08-18 21:30
Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreem…

[ 메디채널 김갑성 기자 ] This innovative platform technology, with exceptional scalability, has been recognized as highly valuable even with limited rights granted. DXVX is taking the lead in business development, with several companies in the due diligence stage, and additional deals are anticipated. SEOUL, South Korea, Aug. 18, 2025 -- Avixgen, a subsidiary of Dx&Vx, announced on the 18th that it has signed a licensing-out agreement worth approximately USD 360 million with a U.S. biotechnology company for its next-generation drug delivery platform, ACP (Advanced Cell Penetrating Pep
- 김갑성 기자
- 2025-08-18 21:00
KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS

Revenue reached approximately RMB950.4 million, with total commercial sales RMB309.8million, representing a significant increase in proportion Research and development expenses was approximately RMB611.5 million Loss for the period was RMB145.2 million; adjusted loss for the period[1] was RMB69.4 million Cash and cash equivalents[2] amounted to approximately RMB4527.8 million, reflecting ample cash reserves Note1: Calculated by deducting equity-settled share-based payment from loss for the year. Note2: Comprises cash and cash eq
- 김갑성 기자
- 2025-08-18 18:29

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 21일 01시 40분